thalidomide has been researched along with Leukemic Infiltration in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Leukemic Infiltration: A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report the case of a 54-year-old African-American male with IgG multiple myeloma (MM) with disease resistant to multiple chemotherapy regimens and immunomodulatory treatment with thalidomide." | 8.82 | Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature. ( Alexandrescu, DT; Koulova, L; Wiernik, PH, 2005) |
| "We report the case of a 54-year-old African-American male with IgG multiple myeloma (MM) with disease resistant to multiple chemotherapy regimens and immunomodulatory treatment with thalidomide." | 4.82 | Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature. ( Alexandrescu, DT; Koulova, L; Wiernik, PH, 2005) |
| " Overall, adverse events were fatigue, constipation, rash, and neuropathy (grade 1 to 2 in most patients)." | 2.70 | Efficacy and safety of thalidomide in patients with acute myeloid leukemia. ( Berdel, WE; Bieker, R; Buechner, T; Kessler, T; Kienast, J; Kropff, M; Mesters, RM; Padró, T; Ruiz, S; Steins, MB, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexandrescu, DT | 1 |
| Koulova, L | 1 |
| Wiernik, PH | 1 |
| Lommatzsch, SE | 1 |
| Bellizzi, AM | 1 |
| Cathro, HP | 1 |
| Rosner, MH | 1 |
| Steins, MB | 1 |
| Padró, T | 1 |
| Bieker, R | 1 |
| Ruiz, S | 1 |
| Kropff, M | 1 |
| Kienast, J | 1 |
| Kessler, T | 1 |
| Buechner, T | 1 |
| Berdel, WE | 1 |
| Mesters, RM | 1 |
1 review available for thalidomide and Leukemic Infiltration
| Article | Year |
|---|---|
Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature.
Topics: Humans; Immunosuppressive Agents; Leukemia, Plasma Cell; Leukemic Infiltration; Male; Middle Aged; M | 2005 |
1 trial available for thalidomide and Leukemic Infiltration
| Article | Year |
|---|---|
Efficacy and safety of thalidomide in patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow; Dose-Response Relation | 2002 |
1 other study available for thalidomide and Leukemic Infiltration
| Article | Year |
|---|---|
Acute renal failure caused by renal infiltration by hematolymphoid malignancy.
Topics: Acute Kidney Injury; Allopurinol; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; D | 2006 |